MRRS adds "Global Diabetes and Obesity Drugs Market to 2022 – Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.

A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.

Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.

The market size for the diabetes and obesity disease cluster is set to increase considerably, driven by the success of a number of T2DM pipeline products, and a rapidly expanding global patient population. However, obesity pipeline activity is set to remain markedly low, despite a patient population of epidemic proportions.

Table of Contents
3 Key Marketed Products 22
3.1 Overview 22
3.2 Diabetes - Top Eight Key Marketed Products 23
3.2.1 Lantus (insulin glargine) - Sanofi 23
3.2.2 Novolog (insulin aspart) - Novo Nordisk 24
3.2.3 Januvia (sitagliptin phosphate) - Merck & Co 25
3.2.4 Levemir (insulin detemir) - Novo Nordisk 26
3.2.5 Victoza (liraglutide) - Novo Nordisk 27
3.2.6 Humalog (insulin lispro) - Eli Lilly 28
3.2.7 Janumet (metformin hydrochloride plus sitagliptin phosphate) - Merck & Co 29
3.2.8 New Market Entrants 30
3.3 Obesity Overview 31
3.3.1 Saxenda (liraglutide) 32
3.3.2 Belviq (lorcaserin hydrochloride) 33
3.3.3 Xenical (orlistat) 34
3.3.4 Contrave (bupropion hydrochloride plus naltrexone) 34
3.4 Conclusion 35
4 Pipeline Landscape Assessment 36
4.1 Overview 36
4.2 Pipeline Development Landscape 37
4.3 Molecular Targets in the Pipeline 40
4.4 Clinical Trials 43
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 43
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 47
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 50
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 53
4.5 Late-Stage Drugs of the Developmental Pipeline 56
4.6 Conclusion 62
5 Multi Scenario Market Forecast to 2022 63......

List of Tables and Figures 
Table 1: Body Mass Index Classifications 10
Table 2: Epidemiology of T1DM, T2DM and Obesity, Global, 2016 15
Table 3: Obesity Therapeutics Market, Seven Major Markets, Summary of the Action, Efficacy and Pathway of the Six Top-Selling FDA-Approved Pharmacotherapeutics, 2015 21
Table 4: Diabetes and Obesity Therapeutics Market, Global, Number of Pipeline Products, 2015 36
Figure 1: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Prevalence (%) and Number of Patients (‘000) with T1DM, 2015-2022 16
Figure 2: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Prevalence (%) and Number of Patients (‘000) with T2DM, 2015-2022 16
Figure 3: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Prevalence (%) and Number of Patients (‘000) with Obesity, 2015-2022 17
Figure 4: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Key Marketed Products and Indications, 2015 23
Figure 5 : Diabetes Therapeutics Market, Global, Annual Revenue for Lantus ($bn), 2006-2022 24
Figure 6 : Diabetes Therapeutics Market, Global, Annual Revenue for Novolog ($bn), 2006-2022 25
Figure 7 : Diabetes Therapeutics Market, Global, Annual Revenue for Januvia ($bn), 2006-2022 26
Figure 8: Diabetes Therapeutics Market, Global, Annual Revenue for Levemir ($bn), 2006-2022 27
Figure 9: Diabetes Therapeutics Market, Global, Annual Revenue for Victoza ($bn), 2006-2022 28 .....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-diabetes-and-obesity-drugs-market-to-2022-insulins-and-gpcrs-retain-commercial-prominence-while-high-unmet-need-remains-in-weight-loss-treatment

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/